Cancer patients in Europe can now receive a life-extending drug invented and developed by scientists at Newcastle University.
Women with recurrent ovarian cancer have been given access to the pioneering treatment, Rubraca®, following approval of the drug by the European Medicines Agency (EMA). This allows the drug to be available on the European market.
Rubraca® has been approved for ovarian cancer patients with a faulty BRCA gene. First discovered approximately 20 years ago, it came out of research initiated at Newcastle University, UK, by Cancer Research UK-funded scientists.
If approved by the National Institute for Health and Care Excellence and the Scottish Medicines Consortium, it will allow ovarian cancer patients in the UK with a BRCA gene mutation to access the new treatment.
Success of treatment
Studies have shown that the oral medication has a high success rate as 54% of women on clinical trials had complete or partial shrinkage of their tumour for an average of 9.2 months.
Ruth Plummer, Clinical Professor of Experimental Medicine at the Northern Institute for Cancer Research, Newcastle University, was the first clinician to prescribe Rubraca®.
Professor Plummer, who is also Consultant Medical Oncologist at Newcastle upon Tyne Hospitals NHS Foundation Trust, said: “It is very exciting and the culmination of
Article originally posted at